Dyne Therapeutics Statistics
Total Valuation
DYN has a market cap or net worth of $2.86 billion. The enterprise value is $2.19 billion.
| Market Cap | 2.86B |
| Enterprise Value | 2.19B |
Important Dates
The next estimated earnings date is Wednesday, November 4, 2026, before market open.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DYN has 186.75 million shares outstanding. The number of shares has increased by 45.37% in one year.
| Current Share Class | 186.75M |
| Shares Outstanding | 186.75M |
| Shares Change (YoY) | +45.37% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | 0.27% |
| Owned by Institutions (%) | 101.07% |
| Float | 186.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 270.82 |
| PB Ratio | 3.77 |
| P/TBV Ratio | 4.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.02, with a Debt / Equity ratio of 0.33.
| Current Ratio | 12.02 |
| Quick Ratio | 11.51 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -36.05 |
Financial Efficiency
Return on equity (ROE) is -81.57% and return on invested capital (ROIC) is -41.23%.
| Return on Equity (ROE) | -81.57% |
| Return on Assets (ROA) | -38.96% |
| Return on Invested Capital (ROIC) | -41.23% |
| Return on Capital Employed (ROCE) | -58.62% |
| Weighted Average Cost of Capital (WACC) | 10.01% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.80M |
| Employee Count | 289 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.04% in the last 52 weeks. The beta is 1.12, so DYN's price volatility has been higher than the market average.
| Beta (5Y) | 1.12 |
| 52-Week Price Change | +9.04% |
| 50-Day Moving Average | 21.20 |
| 200-Day Moving Average | 19.48 |
| Relative Strength Index (RSI) | 30.53 |
| Average Volume (20 Days) | 3,243,761 |
Short Selling Information
The latest short interest is 25.98 million, so 13.91% of the outstanding shares have been sold short.
| Short Interest | 25.98M |
| Short Previous Month | 23.38M |
| Short % of Shares Out | 13.91% |
| Short % of Float | 13.95% |
| Short Ratio (days to cover) | 7.25 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -536.96M |
| Pretax Income | -519.41M |
| Net Income | -519.41M |
| EBITDA | -534.81M |
| EBIT | -536.96M |
| Earnings Per Share (EPS) | -$3.35 |
Balance Sheet
The company has $898.48 million in cash and $233.35 million in debt, with a net cash position of $665.13 million or $3.56 per share.
| Cash & Cash Equivalents | 898.48M |
| Total Debt | 233.35M |
| Net Cash | 665.13M |
| Net Cash Per Share | $3.56 |
| Equity (Book Value) | 702.15M |
| Book Value Per Share | 4.24 |
| Working Capital | 859.86M |
Cash Flow
In the last 12 months, operating cash flow was -$477.82 million and capital expenditures -$21.40 million, giving a free cash flow of -$499.22 million.
| Operating Cash Flow | -477.82M |
| Capital Expenditures | -21.40M |
| Depreciation & Amortization | 2.15M |
| Net Borrowing | 113.03M |
| Free Cash Flow | -499.22M |
| FCF Per Share | -$2.67 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DYN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -45.37% |
| Shareholder Yield | -45.37% |
| Earnings Yield | -18.18% |
| FCF Yield | -17.47% |
Analyst Forecast
The average price target for DYN is $35.73, which is 133.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.73 |
| Price Target Difference | 133.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |